ArticleNMR in biomedicine2006
Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS.
Article in NMR in biomedicine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- The Application of Unsupervised Clustering Methods to Alzheimer's Disease.Frontiers in computational neuroscience · 2019Pooled it
- MRI end-points for clinical trials in ataxias: recommendations from the Ataxia Global Initiative MRI Biomarkers Working Group.Nature reviews. Neurology · 2026Review
- Advances in imaging modalities for spinal tumors.Neuro-oncology advances · 2024Review
- Diagnostic Performance Using a Combination of MRI Findings for Evaluating Cognitive Decline.Journal of the Korean Society of Radiology · 2024Article
- MRI and Clinical Biomarkers Overlap between Glaucoma and Alzheimer's Disease.International journal of molecular sciences · 2023Review
- Penalized decomposition using residuals (PeDecURe) for feature extraction in the presence of nuisance variables.Biostatistics (Oxford, England) · 2023Article
- Review of Progress in Diagnostic Studies of Autism Spectrum Disorder Using Neuroimaging.Interdisciplinary sciences, computational life sciences · 2023Review
- Imaging Methods Applicable in the Diagnostics of Alzheimer's Disease, Considering the Involvement of Insulin Resistance.International journal of molecular sciences · 2023Review
- Transfer learning for cognitive reserve quantification.NeuroImage · 2022Article
- Neurochemical and cognitive changes precede structural abnormalities in the TgF344-AD rat model.Brain communications · 2022Article
- Personalized Healthcare for Dementia.Healthcare (Basel, Switzerland) · 2021Review
- Evaluating the reliability of neurocognitive biomarkers of neurodegenerative diseases across countries: A machine learning approach.NeuroImage · 2020Article
- MR Imaging of SCA3/MJD.Frontiers in neuroscience · 2020Review
- Different Cortical Thinning Patterns Depending on Their Prognosis in Individuals with Subjective Cognitive Decline.Dementia and neurocognitive disorders · 2019Article
- A Novel Approach of Diffusion Tensor Visualization Based Neuro Fuzzy Classification System for Early Detection of Alzheimer's Disease.Journal of Alzheimer's disease reports · 2019Article
- Spinocerebellar ataxias: prospects and challenges for therapy development.Nature reviews. Neurology · 2018Review
- Updated report on tools to measure outcomes of clinical trials in fragile X syndrome.Journal of neurodevelopmental disorders · 2017Review
- Automated identification of dementia using medical imaging: a survey from a pattern classification perspective.Brain informatics · 2016Article
- Various MRS application tools for Alzheimer disease and mild cognitive impairment.AJNR. American journal of neuroradiology · 2014Review
- Cerebral blood flow is an earlier indicator of perfusion abnormalities than cerebral blood volume in Alzheimer's disease.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Neurodegeneration refers to a large clinically and pathologically heterogeneous disease entity associated with slowly progressive neuronal loss in different anatomical and functional systems of the brain. Neurodegenerative diseases often affect cognition, e.g. Alzheimer's disease (AD), dementia with Lewy bodies and vascular dementia, or different aspects of the motor system, e.g., amyotrophic lateral sclerosis, Parkinson's disease and ataxic disorders. Owing to increasing knowledge about the mechanisms leading to neurodegeneration, the development of treatments able to modify the neurodegenerative process becomes possible for the first time. Currently, clinical outcome measures are used to assess the efficacy of such treatments. However, most clinical outcome measures have a low test-retest reliability and thus considerable measurement variance. Therefore, large patient populations and long observation times are needed to detect treatment effects. Furthermore, clinical outcome measures cannot distinguish between symptomatic and disease-modifying treatment effects. Therefore, alternative biomarkers including neuroimaging may take on a more important role in this process. Because MR scanners are widely available and allow for non-invasive detection and quantification of changes in brain structure and metabolism, there is increasing interest in the use of MRI/MRS to monitor objectively treatment effects in clinical trials of neurodegenerative diseases. Particularly volumetric MRI has been used to measure atrophy rates in treatment trials of AD because the relationship between atrophic changes and neuron loss is well established and correlates well with clinical measures. More research is needed to determine the value of other MR modalities, i.e. diffusion, perfusion and functional MRI and MR spectroscopy, for clinical trials with neuroprotective drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.